Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus

Neurocrit Care. 2008;9(2):247-52. doi: 10.1007/s12028-008-9096-5.


Introduction: Posterior reversible encephalopathy syndrome (PRES) is known to occur in association with several substances. However, lysergic acid amide (LSA) is not among the previously reported causes of PRES.

Methods: We report on a patient with PRES presenting as convulsive status epilepticus associated with hypertensive encephalopathy after LSA ingestion. Magnetic resonance imaging was performed and catecholamine metabolites assayed.

Results: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsivant therapy. The clinical history, blood and urinary catecholamine levels, and response to treatment strongly suggest that PRES was induced by LSA.

Conclusion: LSA, a hallucinogenic agent chiefly used for recreational purposes, should be added to the list of causes of PRES.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticonvulsants / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Hallucinogens / adverse effects*
  • Humans
  • Hypertensive Encephalopathy / chemically induced*
  • Hypertensive Encephalopathy / drug therapy
  • Hypertensive Encephalopathy / pathology
  • Lysergic Acid Diethylamide / adverse effects
  • Lysergic Acid Diethylamide / analogs & derivatives*
  • Magnetic Resonance Imaging
  • Male
  • Recovery of Function
  • Status Epilepticus / chemically induced*
  • Status Epilepticus / drug therapy
  • Status Epilepticus / pathology


  • Anticonvulsants
  • Antihypertensive Agents
  • Hallucinogens
  • lysergamide
  • Lysergic Acid Diethylamide